Callan Family Office LLC Makes New Investment in Illumina, Inc. $ILMN

Key Points

• Callan Family Office purchased 10,254 Illumina shares worth approximately $1.8 million in the second quarter. Institutional investors and hedge funds collectively own about 89.4% of the company.
• Illumina reported better-than-expected quarterly results, with EPS of $1.31 and revenue of $1.16 billion, up 9.4% year over year. The company maintained fiscal 2026 EPS guidance of $5.30–$5.40.
• Analyst sentiment remains mixed, with a consensus “hold” rating and an average price target of $188.40, while insiders sold more than 2 million shares worth roughly $401.7 million over the past 90 days.

Callan Family Office LLC purchased a new stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 10,254 shares of the life sciences company's stock, valued at approximately $1,803,000.

Other hedge funds also recently made changes to their positions in the company. Empowered Funds LLC lifted its holdings in shares of Illumina by 113.7% during the 1st quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company's stock worth $737,000 after acquiring an additional 4,940 shares during the period. Sivia Capital Partners LLC bought a new stake in Illumina in the second quarter valued at about $621,000. CW Advisors LLC bought a new stake in Illumina in the second quarter valued at about $275,000. Marshall Wace LLP raised its position in Illumina by 49.0% in the second quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company's stock worth $5,691,000 after purchasing an additional 19,618 shares in the last quarter. Finally, Cresset Asset Management LLC raised its position in Illumina by 30.9% in the second quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company's stock worth $706,000 after purchasing an additional 1,748 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company's stock.

Insider Transactions at Illumina

In related news, SVP Christensen Jakob Wedel sold 1,033 shares of Illumina stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the sale, the senior vice president directly owned 14,023 shares in the company, valued at $2,685,684.96. This trade represents a 6.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 299,336 shares of Illumina stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $217.96, for a total value of $65,243,274.56. Following the completion of the sale, the director owned 1,409,851 shares of the company's stock, valued at approximately $307,291,123.96. The trade was a 17.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 2,095,958 shares of company stock worth $401,720,974. Insiders own 2.90% of the company's stock.

Key Stories Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina’s latest quarterly results exceeded expectations, with earnings of $1.31 per share versus the $1.23 consensus estimate and revenue of $1.16 billion versus expectations of $1.13 billion. Revenue increased 9.4% year over year, while fiscal 2026 EPS guidance remains $5.30-$5.40. Illumina stock information
• Positive Sentiment: Several institutional investors increased their positions, including Marshall Wace, Cresset Asset Management and Empowered Funds. Hedge funds and other institutions collectively own approximately 89.4% of ILMN shares, indicating strong professional-investor participation.
• Neutral Sentiment: Analyst opinions remain mixed. Zacks Research upgraded the stock to “strong buy,” and Leerink Partners raised its target to $210, while Deutsche Bank downgraded the shares to “hold.” The overall consensus rating is “hold,” with an average target of $188.40—below recent trading levels. Analyst coverage of Illumina
• Negative Sentiment: Director Keith A. Meister sold 679,574 Illumina shares from August 19 through August 21 for approximately $145.6 million. The transactions reduced his ownership by roughly one-third, although he still holds about 1.41 million shares. The size and timing of the sales may raise concerns about insider conviction, even though the filings do not establish the reason for the transactions. SEC insider ownership filing
• Negative Sentiment: SVP Christensen Jakob Wedel also sold 1,033 shares under a pre-arranged Rule 10b5-1 trading plan. The smaller, planned transaction is less concerning than Meister’s sales but adds to the recent pattern of insider selling. Illumina insider trading alert

Illumina Stock Performance

ILMN stock opened at $219.40 on Monday. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The company has a 50 day moving average price of $188.01 and a 200 day moving average price of $152.52. Illumina, Inc. has a fifty-two week low of $88.00 and a fifty-two week high of $220.43. The stock has a market capitalization of $33.13 billion, a PE ratio of 40.93, a price-to-earnings-growth ratio of 3.09 and a beta of 1.45.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.08. The firm had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The business's revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Analysts forecast that Illumina, Inc. will post 5.36 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. JPMorgan Chase & Co. lifted their price objective on Illumina from $220.00 to $230.00 and gave the company an "overweight" rating in a report on Friday, July 31st. Sanford C. Bernstein reissued a "market perform" rating and issued a $215.00 target price on shares of Illumina in a report on Friday, July 31st. Canaccord Genuity Group raised their target price on Illumina from $190.00 to $205.00 and gave the stock a "hold" rating in a research report on Monday, August 3rd. Wall Street Zen raised Illumina from a "hold" rating to a "buy" rating in a research note on Saturday, August 1st. Finally, Weiss Ratings upgraded Illumina from a "hold (c-)" rating to a "hold (c)" rating in a research report on Wednesday, June 3rd. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $188.40.

Illumina Company Profile

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source